🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Goldman Sachs bullish on Becton Dickinson stock, citing new product growth

EditorEmilio Ghigini
Published 30/05/2024, 10:04
BDX
-

On Thursday, Goldman Sachs (NYSE:GS) initiated coverage on Becton Dickinson (NYSE:BDX) stock with a Buy rating and a price target of $274.00.

The firm's outlook is based on the anticipation of a prolonged phase of above-market revenue growth, driven by the launch of new products.

Becton Dickinson is expected to experience a shift in earnings momentum, according to the investment bank's analysis. This shift is projected to result in a 10% earnings growth through the fiscal year 2027.

The firm's optimistic stance on Becton Dickinson's stock comes after a period of approximately 1% earnings per share (EPS) growth from the fiscal year 2019 through the fiscal year 2023, during which the company's share price remained relatively stagnant.

The analyst from Goldman Sachs highlighted that the company's improved revenue growth, coupled with diminishing cost pressures, is likely to contribute to the positive earnings trajectory. This development represents a significant turnaround from the flat share price performance observed over the past four years.

Becton Dickinson's focus on innovation and product development is central to the firm's forecast of the company's above-market top-line growth.

The medical technology firm's strategic direction appears to align with Goldman Sachs' criteria for a stock worthy of a Buy rating.

The price target set by Goldman Sachs at $274.00 suggests confidence in Becton Dickinson's ability to capitalize on market opportunities and enhance shareholder value through its business initiatives.

The new coverage and price target provide investors with a perspective on the company's potential financial performance in the coming years.

InvestingPro Insights

As Becton Dickinson (NYSE:BDX) garners a favorable outlook from Goldman Sachs, real-time data and insights from InvestingPro further illuminate the company's financial landscape. With a robust market capitalization of $65.05 billion, BDX stands out as a significant player in the Healthcare Equipment & Supplies industry. A testament to its stability and investor confidence, BDX has a history of raising its dividend, now for 54 consecutive years, showcasing a strong commitment to shareholder returns. The company's current dividend yield is at 1.69%, reflecting this ongoing dedication to providing shareholder value.

InvestingPro Tips indicate that BDX is expected to see net income growth this year, aligning with Goldman Sachs' analysis of the company's earnings momentum. Additionally, BDX's stock is known for its low price volatility, suggesting it may be a suitable choice for investors seeking stability in their portfolio. For those looking into deeper analysis, InvestingPro offers a range of additional tips to guide investment decisions. Currently, there are 9 more tips available for BDX, which can be accessed for further strategic insights.

Investors interested in BDX can take advantage of a special offer to access these valuable insights: use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. This promotion provides an excellent opportunity to leverage the comprehensive analysis provided by InvestingPro to make informed investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.